FDA grants accelerated approval to Trodelvy for the treatment of metastatic urothelial cancer – Gilead Sciences
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC)… read more.